Ferroptosis is a non-apoptotic form of regulated cell death caused by the failure of the glutathione-dependent lipid-peroxidescavenging network. FINO 2 is an endoperoxide-containing 1,2-dioxolane that can initiate ferroptosis selectively in engineered cancer cells. We investigated the mechanism and structural features necessary for ferroptosis initiation by FINO 2 . We found that FINO 2 requires both an endoperoxide moiety and a nearby hydroxyl head group to initiate ferroptosis. In contrast to previously described ferroptosis inducers, FINO 2 does not inhibit system x c or directly target the reducing enzyme GPX4, as do erastin and RSL3, respectively, nor does it deplete GPX4 protein, as does FIN56. Instead, FINO 2 both indirectly inhibits GPX4 enzymatic function and directly oxidizes iron, ultimately causing widespread lipid peroxidation. These findings suggest that endoperoxides such as FINO 2 can initiate a multipronged mechanism of ferroptosis.
R egulated cell death includes several processes that lead to cell death through specific mechanisms that can be modulated with pharmacological and genetic tools. The recognition of cell death as a regulated process began with the discovery and characterization of apoptosis 1, 2 . Ongoing work has since uncovered several other regulated cell death processes, including ferroptosis. Ferroptosis is an iron-dependent, oxidative form of regulated cell death that is distinct from apoptosis and is characterized by the failure of the glutathione (GSH)-dependent lipid peroxide defense network [3] [4] [5] . Consequently, cells undergoing ferroptotic cell death exhibit an increased accumulation of lipid peroxides and cannot be rescued by inhibitors of apoptosis or other cell death processes 6 .
Organic peroxides, such as artemisinin (1 ) and artesunate (2 ) , are used therapeutically as cytotoxic agents for the treatment of cancers [7] [8] [9] . Recently, development of analogs based on the plakinic acid natural products (3 ) identified the 1,2-dioxolane FINO 2 (4 ) , which triggers ferroptosis (Fig. 1a) 10 . Further evaluation of ferroptosis induction by FINO 2 against multiple cancer lines revealed that FINO 2 selectively initiates ferroptosis in BJ-eLR cancer cells compared to the isogenic, noncancerous BJ-hTERT cell line 10 . Since evasion of apoptotic signaling is a hallmark of cancer 11 , the ability of FINO 2 to initiate a non-apoptotic programmed cell death process selectively in tumorigenic cells makes it an attractive target for further study.
Here, we sought to define the mechanism by which FINO 2 induces ferroptosis and determine which structural features of FINO 2 are necessary for its function. These experiments demonstrate that, in contrast to other ferroptosis-inducing compounds such as erastin, FINO 2 does not deplete GSH through the inhibition of system x c -. FINO 2 instead bypasses GSH depletion to cause iron oxidation, as well as loss of activity of the lipid-peroxide-reducing enzyme GPX4 indirectly, by a mechanism that is distinct from that of other GPX4 inhibitors. Exploration of the structure-activity relationship around the FINO 2 scaffold revealed that both the endoperoxide moiety and the pendant hydroxyethyl group are necessary to induce oxidative events leading to ferroptotic cell death. We found that FINO 2 exerts dual effects involving iron oxidation and loss of GPX4 enzymatic activity to induce ferroptosis, and it therefore represents a distinct class of ferroptosis inducers.
Results
FINO 2 induces ferroptosis. We initially sought to evaluate the lethality of FINO 2 in a cell line in which ferroptosis had been previously examined. Ferroptosis-sensitive HT-1080 fibrosarcoma cells 3 were treated with a lethal concentration of FINO 2 (10 μ M) ( Supplementary Fig. 1a ) alone or along with a panel of death-suppressing compounds at varied concentrations (Fig. 1b) . The lethality of FINO 2 was suppressed by the ferroptosis inhibitor ferrostatin-1, which prevents the accumulation of lipid peroxides, likely through a radical-trapping mechanism 12, 13 . Baicalein and Trolox, which have been reported to inhibit ferroptosis 6 , both suppressed FINO 2 lethality (Fig. 1b) . The apoptosis inhibitor zVAD-FMK was unable to suppress cell death. Necrostatin-1, an inhibitor of necroptosis, an alternative form of regulated cell death, was similarly unable to prevent FINO 2 -induced death. We also evaluated the ability to suppress FINO 2 lethality of nitroxide antioxidants XJB-5-131 and JP4-039, which were previously found to suppress ferroptosis 14 . The mitochondria-targeted nitroxide XJB-5-131 was 39-fold more potent than the cytosolic JP4-039, highlighting the potential importance of mitochondrial lipid peroxidation in mediating FINO 2 lethality ( Supplementary Fig. 1 ).
We next aimed to validate the finding that FINO 2 causes lipid peroxidation, a defining event in ferroptosis. HT-1080 cells were treated with either FINO 2 or the ferroptosis inducer erastin, and the increase in fluorescence intensity of the fluorescent lipid peroxidation probe C11-BODIPY was monitored by flow cytometry (Fig. 1c) 3 . Both erastin and FINO 2 showed an increase in fluorescence 6 h after treatment, with FINO 2 showing a much larger shift, suggesting that FINO 2 causes a more rapid onset or overall greater quantity of lipid peroxidation. This increase was suppressed by cotreatment with deferoxamine (DFO), an iron chelator, confirming the iron dependence of lipid peroxidation induced by both FINO 2 and erastin. We examined the oxidation of endogenous lipids by measuring the accumulation of thiobarbituric acid-reactive substances (TBARS) in cells treated with erastin or FINO 2 (Fig. 1d ). This assay detects malondialdehyde, a common product from the degradation of multiple lipid species 15 . FINO 2 -treated cells showed a greater increase in TBARS than did erastin. In both cases, cotreatment with ferrostatin-1 suppressed TBARS accumulation, indicating the presence of lipid peroxidation suppressible by a specific ferroptosis inhibitor.
To gain insight into the type of lipid oxidation caused by FINO 2 , we used liquid chromatography-mass spectrometry (LC-MS) analysis to measure the oxidation of phosphatidylethanolamine (PE), a lipid critical to the propagation of ferroptosis ( Fig. 1e and Supplementary Fig. 2) 16 . FINO 2 treatment caused a large increase in a diverse set of oxidized PE species. Not all PEs that were oxidized in response to FINO 2 had their oxidation suppressed by cotreatment with ferrostatin-1, suggesting that only a specific set of oxidized PE species contribute to ferroptosis.
FINO 2 does not alter glutathione homeostasis.
Having validated the finding that FINO 2 causes ferroptosis in HT-1080 cells, we sought to define the mechanism by which FINO 2 induces ferroptosis in these cells. Originally, ferroptosis-inducing compounds were divided into two classes. Class 1 ferroptosis inducers decrease intracellular GSH, a necessary cofactor for the lipid-peroxide-reducing enzyme GPX4. Class 2 ferroptosis inducers inhibit GPX4 directly through active site inhibition. More recently, the small molecule FIN56 was reported to deplete GPX4 protein and also to deplete coenzyme Q10, an endogenous inhibitor of lipid peroxidation, through modulation of the mevalonate pathway 17 .
A major source of cysteine for GSH synthesis is the cystine/glutamate antiporter, system x c -( Supplementary Fig. 3 ). Inhibition of . P values were determined using one-way ANOVA; *P = 0.003, **P < 0.001 versus DMSO control. e, Changes in oxidized PE abundance as detected by LC-MS after treatment with FINO 2 (10 μ M) for 6 h. Individual lipid species are plotted with their log 2 (fold change in abundance) on the horizontal axis and the statistical significance of the change (log 10 (P)) on the vertical axis. P values were determined using two-sided t-tests. Lipid species with significant change upon FINO 2 treatment fall above the dashed line (P < 0.05). Experiments were performed in triplicate with biologically independent samples. system x c by erastin, sulfasalazine, sorafenib or glutamate depletes intracellular GSH and induces ferroptosis 18 . To test whether FINO 2 acts via system x c inhibition and GSH depletion, we examined the ability of FINO 2 to inhibit system x c function using a fluorescent enzymatic assay that quantifies the amount of glutamate released by cells into glutamate-free medium ( Fig. 2a) 18 . Both erastin and sulfasalazine were able to inhibit glutamate release compared to vehicle-treated cells. FINO 2 showed minimal inhibition of glutamate release, suggesting that inhibition of system x c is not a primary mechanism of FINO 2 lethality. We also quantified glutathione in cells undergoing ferroptosis using a reactive fluorescent reporter of free thiols in cell lysates (Fig. 2b ). To eliminate nonspecific reactivity with accessible cysteine residues on proteins, we precipitated the protein fraction of lysates, leaving GSH as the major thiol in solution 19 . Cells treated with erastin exhibited a threefold decrease in GSH content compared to cells treated with vehicle or the GPX4 inhibitor (1S,3R)-RSL3, hereafter referred to as RSL3. FINO 2treated cells showed no decrease in thiol content, indicating that FINO 2 does not deplete GSH. These results suggest that FINO 2 is not a system x c inhibitor and does not deplete GSH through other mechanisms.
The oxidative stress caused by erastin upregulates components of the endoplasmic reticulum (ER) stress response pathway. The GSHspecific γ -glutamylcyclotransferase enzyme encoded by the CHAC1 gene has been observed to be a pharmacodynamic marker of exposure to erastin 18 . To test whether FINO 2 induces transcriptional changes similar to those of other ferroptosis inducers, we performed reverse transcription and quantitative PCR to quantify the amount of CHAC1 mRNA in cells treated with erastin or FINO 2 (Fig. 2c ). Cells treated with FINO 2 showed a sevenfold increase in CHAC1 mRNA compared to vehicle. This upregulation was nearly threefold less than the upregulation in cells treated with erastin. This more modest upregulation indicates that FINO 2 induces different transcriptional responses than an equivalent concentration of erastin.
FINO 2 indirectly inhibits GPX4 activity in cells.
Because FINO 2 does not display the characteristic functional or genetic hallmarks of a class 1 ferroptosis inducer, we next evaluated the ability of FINO 2 to act as a class 2 ferroptosis inducer by inhibiting GPX4 enzymatic activity. GPX4 is a selenocysteine-containing enzyme responsible for reducing lipid hydroperoxides to lipid alcohols, making it a master regulator of ferroptotic signaling ( Supplementary Fig. 3 ). To understand the impact of FINO 2 on GPX4 activity, we used an LC-MS-based assay to monitor the ability of GPX4-containing lysates collected from cells treated with vehicle or ferroptosis inducers to reduce the GPX4-specific substrate phosphatidylcholine hydroperoxide (PCOOH) ( Supplementary Fig. 4) 4, 17 . Whereas erastin-treated cells did not show reduced GPX4 activity in this assay, treatment of cells with FINO 2 , FIN56 or RSL3 decreased the activity of GPX4 in the resulting lysates to a similar extent. We next monitored the kinetics of GPX4 inhibition by RSL3 and FINO 2 by varying the amount of time cells were incubated with either compound. We observed that RSL3 caused a more rapid inhibition of GPX4 activity than did FINO 2 ( Supplementary Fig. 5 ), suggesting that FINO 2 might have a distinct mechanism of action from RSL3.
The observation that FINO 2 caused decreased GPX4 activity suggested that, like RSL3, FINO 2 might be a direct inhibitor of GPX4 4, 6 or that FINO 2 could deplete GPX4 protein, similarly to the ferroptosis inducer FIN56 17 . To test whether FINO 2 is a direct inhibitor of GPX4, we again used the LC-MS-based PCOOH reduction assay to monitor the reduction of PCOOH in GPX4-containing cell lysates treated with ferroptosis inducers after cell lysis ( Fig. 3a ). Because ferroptosis inducers are added after cell lysis, only molecules capable of directly inhibiting active GPX4 can prevent PCOOH reduction. As expected, the direct GPX4 inhibitor RSL3 was able to prevent PCOOH reduction in this assay ( Fig. 3a ). FINO 2 was unable to prevent PCOOH reduction, even at elevated concentrations, suggesting that FINO 2 is not a direct inhibitor of GPX4. To support our hypothesis that FINO 2 does not directly interact with GPX4, we performed 1 H-15 N heteronuclear single quantum coherence (HSQC) NMR spectroscopy on GPX4 U46C in the presence and absence of FINO 2 . Unlike RSL3, FINO 2 did not cause a change in the HSQC spectrum of GPX4, indicating that FINO 2 is neither an allosteric nor active site ligand of GPX4 ( Fig. 3b and Supplementary Fig. 6 ).
Gene PTGS2, which encodes prostaglandin synthase, is upregulated following RSL3 treatment 4 . We determined whether cells experienced a similar upregulation following treatment with FINO 2 . FINO 2 and erastin showed less upregulation of PTGS2, than RSL3, indicating that FINO does not cause the same transcriptional changes as the class 2 ferroptosis inducer RSL3 ( Fig. 3c ).
To evaluate whether FINO 2 acts as an irreversible covalent inhibitor of GPX4, HT-1080 cells were treated with a lethal dose of each ferroptosis inducer and either vehicle, ferrostatin-1 or β -mercaptoethanol (β -ME) ( Fig. 3d ). In the extracellular medium, β -ME reacts with cystine to form a disulfide bond with cysteine. Neutral amino acid transporters import this mixed disulfide, bypassing system x c and increasing intracellular cysteine availability 20 . When cells are cotreated with RSL3 and β -ME, the increase in cysteine availability for GSH synthesis is unable to rescue cells because GPX4 is irreversibly and covalently inhibited. Conversely, the lethality of erastin is fully suppressed by β -ME, as cysteine availability is no longer dependent on system x c function. β -ME also rescued ferroptosis induced by FIN56, which depletes GPX4 protein abundance ( Fig. 3d) 17 . β -ME may prevent FIN56 lethality by increasing the cysteine available for GSH synthesis, thereby improving the activity of the remaining GPX4 21 . Ferroptosis induced by FINO 2 was partially rescued by β -ME, further indicating that FINO 2 is not an irreversible covalent inhibitor of GPX4. Since FINO 2 does not decrease intracellular glutathione (Fig. 2b ), we reasoned that β -ME supplementation might rescue FINO 2 -treated cells by enhancing GPX4 activity, similarly to the situation with FIN56.
To test whether FINO 2 causes GPX4 protein depletion similarly to FIN56, we quantified the abundance of GPX4 protein in cells undergoing ferroptosis by western blotting ( Fig. 3e and Supplementary Fig. 7 ). As expected, both RSL3 and FIN56 caused a large decrease in the abundance of GPX4 at the protein level 17 . Erastin and FINO 2 caused only a minor decrease in GPX4 protein abundance, suggesting that FINO 2 is unlike FIN56.
The endoperoxide moiety is required for FINO 2 lethality. Since FINO 2 does not display behavior characteristic of a class 1 or class 2 ferroptosis inducer, we sought to gain insight into its mechanism by determining which functional groups in FINO 2 are required for inducing ferroptosis. Earlier reports indicated that the ether linkage in artemisinin dimers may be more critical for cytotoxic activity than the endoperoxide component 22, 23 . Therefore, we prepared a series of nonperoxide derivatives of FINO 2 .
The first derivatives synthesized possessed a spirocyclic oxetane unit. These derivatives can be viewed as analogs in which an oxygen atom was removed from the peroxide functional group. Earlier studies indicate that spirocyclic oxetanes, which are emerging as effective drug candidates, are cytotoxic toward cancer cells 24, 25 . The spirocyclic oxetanes were synthesized from cyclohexanones 5 -7 in three steps. Addition of allylmagnesium chloride afforded alkenes 8 -10 26, 27 . Treatment of these alkenes with meta-chloroperoxybenzoic acid (-mCPBA) yielded epoxides 11 -13 . These epoxides were then heated under basic conditions to afford oxetanes 14 -16 28 . During attempts to synthesize the O-axial diastereomers, however, rapid elimination of water occurred under the strongly basic conditions required for cyclization 29 .
Similar methodology was used to prepared tetrahydrofuran derivatives of FINO 2 . These furans were selected because they maintain the same-sized rings as found in FINO 2 while removing the peroxide functional group. Terpenoid-derived spirocyclic furans are reported to induce apoptosis in a range of cancers, with halfmaximal inhibitory concentration values in the low micromolar range 30 . Other fused-ring furans have shown biological activity for a range of diseases 31 . The spirocyclic furan derivatives were prepared from cyclohexanone 5 in two steps. Homoallylation of ketone 5 afforded alkenes 17a and 17b . Upon exposure to the epoxidation conditions, tetrahydrofurans 18a and 18b were formed. This intramolecular cyclization is likely to occur by cyclization of the hydroxyl group onto a protonated epoxide intermediate 32 . Avoiding the basic cyclization step allowed us to prepare a FINO 2 derivative with an axial oxygen atom (18a ). Another derivative of FINO 2 was synthesized by ring expansion. Hydrogenation of the oxygen− oxygen bond in FINO 2 yielded triol 19 . Subsequent protection of this triol with benzyl bromide occurred only at the primary hydroxyl group, forming 1,3-diol 20 . Protection of this 1,3-diol with dibromomethane afforded 1,3-dioxane 21 . Deprotection of the benzyl group yielded the desired 1,3-dioxane analog 22 . We considered triol 19 to also be an analog of FINO 2 that warranted cell studies. Considering the reducing environment of the cell 33 , FINO 2 could act as a prodrug, forming triol 19 . Thus, the activity of FINO 2 could be due to the reduced product, as observed for some other peroxide-based drugs 34, 35 .
We measured the activities of FINO 2 and its analogs in several cell lines. These cells included the renal cancer cell line CAKI-1 and two immortalized fibroblast cell lines, BJ-hTERT and its tumorigenic counterpart BJ-eLR. Activities were measured using the CellTiter-Glo assay (Fig. 4a ). In all cases, the nonperoxide compounds displayed essentially no activity. FINO 2 , however, was able to kill oncogenic BJ-eLR and CAKI-1 cells selectively compared to BJ-hTERT cells. This result suggested that the peroxide moiety was essential for the induction of ferroptosis.
Earlier studies have also reported biological activity of 1,2-dioxolane-containing natural products, such as the plakinic acids and plakortides 36, 37 . To determine the general ability of 1,2-dioxolanes to initiate ferroptosis, we synthesized a series of peroxide-containing FINO 2 analogs. These synthetic analogs had modifications of both the hydrophobic and hydrophilic moieties while retaining the 1,2-dioxolane core. The 1,2-dioxolanes were synthesized from ketones 5 − 7 and 34 . Treatment with LiN i Pr 2 yielded silyl enol ethers 23 − 25 and 35 38 . Regioselective cobalt-catalyzed peroxidation of these products furnished mixed peroxyketals 26 − 28 and 36 38 . Treatment of these compounds with 5 mol% of SnCl 4 and alkene 29 , 30 , 38 or 40 followed by immediate deprotection yielded FINO 2 (4 ) and derivatives 31 − 33 , 37 , 39 and 41 38 .
These 1,2-dioxolanes were tested in the renal cancer cell line (CAKI-1) along with both 10,12-peroxycalamenene (42 ) 37 and artemisinin (1 ) (Fig. 4b ). We selected these natural products because 10,12-peroxycalamenene has been shown to induce apoptosis in human breast carcinoma cells 39 , and several studies have reported on artemisinin's activity against cancer [7] [8] [9] [40] [41] [42] .
The structure-activity relationship studies suggest that FINO 2 belongs to a class of ferroptosis-inducing compounds that are somewhat tolerant of modifications while retaining biological activity, unlike RSL3. Moving the tert-butyl group of FINO 2 from C-4 to C-3 (31 ) resulted in a small decrease in potency. Removing the polar functionality (32 ) revealed that, although a peroxide moiety is necessary for initiating ferroptosis, it is not sufficient. Increasing the distance between the peroxide bond and hydroxyl group (41 ) also resulted in a decrease in activity. These data demonstrate that the hydroxyl portion of FINO 2 must be present and have a specific spatial relationship to the peroxide, suggesting a specificity of mechanism for FINO 2 . Observations of cytotoxic activity of naturally occurring peroxides noted a similar requirement 37 .
The tert-butyl group, which can be metabolically unstable 43 , is not required. When that group was replaced with an aromatic ring, 1,2-dioxolane 33 was similarly potent. Retaining the spirobicyclic core structure of FINO 2 was also not necessary. Monocyclic peroxide 37 , an analog that resembles plakinic acid J (3 ) (Fig. 1a) , displayed activity similar to FINO 2 . The activity of 37 suggests that the cytotoxicity of 3 may be due to ferroptosis, not apoptosis 36, 37 . As observed for peroxide natural products 37 , hydrophobic analog 39 was also inactive. FINO 2 is a stable oxidant that oxidizes ferrous iron. Since the peroxide moiety in FINO 2 is necessary for inducing ferroptosis, we hypothesized that FINO 2 might be a selective pro-oxidant molecule that initiates ferroptosis through specific oxidation of ferroptosis-relevant substrates. Consistent with this hypothesis of relative inertness to most substrates, FINO 2 was previously determined to be stable to 150 °C by thermogravimetric analysis 10 . Similar 1,2-dioxolanes have also shown stability to LiBH 4 and LiEt 3 BH, strong hydride reducing agents, at room temperature 44 .
Subjection to these high temperatures and strong reducing conditions, however, are not necessarily biologically relevant. We therefore subjected FINO 2 to a variety of biologically relevant redox conditions in vitro ( Supplementary Fig. 8 ) and monitored for reaction by 1 H-NMR spectroscopy. Heating FINO 2 at 37 °C with a thiol, a class of compounds that are typically found at 0.5− 10 mM in human cells 19 , yielded no decomposition. FINO 2 was found to be stable to GSH, in agreement with the observation that FINO 2 did not deplete GSH (see above). Arachidonic acid, a ubiquitous polyunsaturated fatty acid in cell membranes, showed no degradation following treatment with FINO 2 . Selenium-containing compounds such as selenocysteine and ebselen, the latter of which is a model for GPX4 45 , also did not reduce the peroxide bond. The inability of ebselen to reduce FINO 2 is consistent with the observation that GPX4 cannot reduce endoperoxides 46 . Ebselen was only able to reduce FINO 2 at 90 °C, which suggests that FINO 2 does not readily degrade to its reduced form 19 or to reactive oxygen species to confer biological activity. These results, along with the lack of reactivity toward most reducing agents, suggest that the intact endoperoxide form is responsible for activity. FINO 2 was also stable at varying pH. No reaction was observed with amines or strong bases, even under conditions beyond the basicity found in peroxisomes 47 . FINO 2 was also found to be stable under acidic conditions that mimic conditions found in lysosomes 48 . To examine the stability of FINO 2 in biological systems, we measured the stability of FINO 2 in human and mouse plasma and liver microsomes. We found that FINO 2 had high stability in plasma and human microsomes ( Supplementary Fig. 9 ).
Analogously to Fenton chemistry, 1,2-dioxolanes and ferrous iron can generate oxygen-centered radicals that initiate oxidative damage in biological systems 44 . We hypothesized that FINO 2 might initiate Fenton-type chemistry selectively over other organic peroxides 3, 12 . Using an in vitro colorimetric assay, we monitored the oxidation state of iron treated with oxidizing compounds (Fig. 5a ). Out of all tested organic peroxides, only FINO 2 and tert-butyl hydroperoxide ( t BuOOH) were able to oxidize ferrous iron in vitro ( Fig. 5a ). Cell death initiated by t BuOOH cannot be suppressed by ferrostatin-1 or β -ME ( Supplementary Fig. 10 ), indicating that the lethality of t BuOOH cannot be attributed to ferroptosis.
The iron oxidation by FINO 2 is accompanied by a degradation of the endoperoxide. Incubation of FINO 2 at 37 °C for 12 h reveals reduction of the peroxide bond by FeSO 4 , as seen in similar systems (Fig. 5b) 49 . This reduction is consistent with studies on 1,2,4-trioxolanes and plakortin derivatives that suggest rapid reduction of the peroxide functionality 34, 35, 49, 50 . Consistent with previous studies, artesunate (2 ) also decomposed after exposure to iron ( Supplementary Fig. 11 ) 7 . Inactive analogs 32 and 41 were only partially decomposed after iron exposure ( Supplementary Fig. 11 ). These results suggest that the complete breakdown of the peroxide moiety by iron is required to induce ferroptosis.
The selectivity of iron oxidation by FINO 2 compared to analogs 32 and 41 suggested that iron oxidation might be important to ferroptosis initiation by FINO 2 . The iron chelator DFO is able to suppress the lethality of FINO 2 tenfold more potently than that of erastin or RSL3 (Fig. 5c ). Similarly, supplementation of cell medium with ferrous or ferric salts sensitized cells to FINO 2 -initiated ferroptosis, but not to RSL3-initiated ferroptosis ( Supplementary Fig. 12 ). Despite the apparent importance of iron to FINO 2 lethality, FINO 2 treated cells did not show changes in the abundance of the iron regulatory proteins IRP2, FTL1 or TFR ( Supplementary Fig. 13 ), suggesting that FINO 2 may engage labile cellular iron preferentially over iron-containing proteins.
FINO 2 oxidizes the lipidome independent of ALOX activity.
Previously, the family of arachidonic acid lipoxygenases (ALOX) was shown to be critical in generating lipid peroxides during ferroptosis, particularly in response to erastin or RSL3 6 . siRNA knockdown of either the ALOX15B or ALOXE3 genes suppressed the lethality of erastin. Similarly, a GFP-ALOX5 fusion protein expressed in ferroptosis-sensitive cells was activated and translocated to the nuclear membrane following erastin treatment. Because FINO 2 is able to oxidize ferrous iron directly, we sought to evaluate whether ferroptosis initiated by FINO 2 required enzymatic lipid peroxidation, similarly to that initiated by erastin and RSL3. We assembled a collection of arachidonic acid derivatives deuterated at the bis-allylic positions. Deuteration at the bis-allylic position creates a strong kinetic isotope effect in lipoxygenase enzymes, making deuterated arachidonic acids effective and highly specific inhibitors of lipoxygenases (Fig. 6a) .
We incubated HT-1080 cells with vehicle only (0.1% ethanol), arachidonic acid or a deuterated arachidonic acid overnight to allow incorporation of the fatty acid into cellular membranes. Cells were then treated with erastin, RSL3 or FINO 2 (Fig. 6b ). Deuteration at the 7 position was strongly protective against cell death initiated by erastin and RSL3, confirming the importance of ALOX5 in initiating ferroptosis for these molecules. Ferroptosis induced by FINO 2 was only weakly rescued by deuteration at the 7 position, suggesting that FINO 2 either activates an ALOX isoform with different regioselectivity or preferentially oxidizes fatty acid groups other than arachidonic acid. To evaluate whether FINO 2 activates a different lipoxygenase isoform than erastin or FINO 2 , we tested all combinations of deuterated arachidonic acid analogs against all ferroptosis inducers. Additional deuteration increased the amount of death suppression for erastin and RSL3, and the fully deuterated D 6 -arachidonic acid completely suppressed the lethality of both of these ferroptosis inducers. No significant suppression of ferroptosis initiated by FINO 2 was observed for any deuterated arachidonic acid tested ( Fig. 6b ), suggesting that FINO 2 does not require ALOXmediated peroxidation for ferroptosis induction.
To compare the global lipidomic changes following treatment with FINO 2 or erastin, we used LC-MS to identify oxidized esterified phospholipids extracted from HT-1080 cells treated with vehicle (DMSO), FINO 2 or erastin with and without ferrostatin-1. Because of its importance to ferroptosis, we first compared the changes in oxidized PE following treatment with either ferroptosis inducer at equivalent time points (Fig. 6c ). Whereas erastin caused an increase in 1 PE species after treatment, FINO 2 caused an increase in 21 PE species ( Supplementary Fig. 2 ). This pattern was consistent for other phospholipids, including phosphatidylcholine, phosphatidylinositol, phosphatidylserine and cardiolipin (Fig. 6d) . The increases in oxidized phosphatidylserine and cardiolipin were unresponsive to ferrostatin treatment, suggesting they do not contribute to ferroptosis ( Supplementary Fig. 2b ). MS analysis allowed us to identify the acyl tail portions of the oxidized phospholipids. As expected, all acyl tails contained some degree of polyunsaturation. Many of the oxidized phospholipids contained linoleic (18:2), arachidonic (20:4) and other polyunsaturated moieties. Cumulatively, these data show that FINO 2 causes the oxidation of a much more diverse set of phospholipids than does erastin, and does not have strong substrate selectivity within the set of polyunsaturated lipids.
Discussion
A common feature of all ferroptosis inducers is the ability to overcome the endogenous GSH-dependent lipid peroxidation defense network. In this study, we investigated the mechanism by which the 1,2-dioxolane FINO 2 is able to induce ferroptosis in cells. FINO 2 did not elicit the same transcriptional, translational and phenotypic responses expected from previously described ferroptosis inducers. We hypothesize that FINO 2 is able to initiate ferroptosis through a combination of its abilities to directly oxidize labile iron and inactivate GPX4.
In support of this hypothesis, we found that the highly oxidizing peroxide group and a nearby polar head group were both required for lethality and for oxidation of ferroptosis-relevant substrates. Neither nonperoxide derivatives nor nonpolar derivatives of FINO 2 were lethal to cells. Elongation of the polar head group led to a loss in activity as well as an inability to oxidize iron, suggesting that the spatial relationship between the peroxide and hydroxyl moieties in FINO 2 is required to engage labile iron or may facilitate the reduction of the oxygen-oxygen bond. Ferroptosis initiation by FINO 2 is highly sensitive to iron availability and involves oxidation of a broad set of polyunsaturated lipids. Unlike other peroxide-containing compounds, FINO 2 is able to initiate ferroptosis preferentially over other forms of cell death. Multiple factors could account for this remarkable selectivity, including inactivation of GPX4 or the lipophilicity of FINO 2 . The predicted octanol/water partition coefficient (SlogP) for FINO 2 is 3.54, whereas the value for artemisinin is 2.39, making FINO 2 more than an order of magnitude more lipophilic than artemisinin. Because of its high lipophilicity, FINO 2 may accumulate in the appropriate lipid bilayers of cell membranes, allowing it to oxidize polyunsaturated fatty acids directly in the locations that trigger ferroptosis.
In summary, this study provides insight into the mechanism of ferroptosis by FINO 2 and offers new perspectives on how ferroptosis can be initiated. Structural exploration of FINO 2 and its analogs revealed that this new class of ferroptosis inducer can be modified and retain biological activity, but requires the endoperoxide and hydrophilic head to be present. In addition, whereas previous ferroptosis initiators inhibited components of the endogenous lipidperoxide-scavenging network in cells, FINO 2 induces ferroptosis through a combination of direct oxidation of ferroptosis-relevant substrates and indirect GPX4 inactivation. The mechanism of GPX4 inactivation by FINO 2 remains unclear, since FINO 2 does not decrease levels of GPX4 protein and is not a GPX4 ligand. Nonetheless, we hypothesize that this specific combination of prooxidant functionality and GPX4 inactivation is required to navigate cells to ferroptosis in response to this class of compounds.
Methods
Methods, including statements of data availability and any associated accession codes and references, are available at https://doi. org/10.1038/s41589-018-0031-6. 
C11-BODIPY lipid peroxidation measurement.
The day before the experiment, 600,000 HT-1080 cells were seeded in six-well plates and allowed to adhere overnight at 37 °C. On the day of the experiment, cells were treated with DMSO, erastin (10 μ M) or FINO 2 (10 μ M) with or without DFO (100 μ M) and incubated for 6 h at 37 °C. Cells were trypsinized, washed, suspended in HBSS containing 1.5 μ M C11-BODIPY (ThermoFisher) and incubated at 37 °C for 15 min. Cells were pelleted and resuspended in HBSS. Fluorescence intensity was measured on the FL1 channel with gating to record live cells only (gate constructed from DMSO treatment group). A minimum of 10,000 cells was analyzed per condition.
Reduced glutathione measurement. Ten million HT-1080 cells were treated with 5 µ M erastin, 10 µ M FINO 2, 500 nM RSL3 or vehicle. Cells were harvested after 1.5 h (RSL3) or 6 h (vehicle, erastin, FINO 2 ) and lysed using ice-cold PBS containing 0.5% Nonidet P-40. Samples were centrifuged for 15 min at 4 °C at 17,000g. The resulting supernatant was deproteinized using a deproteinizing kit (ab2047080, Abcam) and kept on ice. Reduced GSH levels were determined using GSH/GSSG Ratio Detection Assay Kit (Fluorometric -Green) (ab138881, Abcam) following the manufacturer's protocol. LC-MS analysis of in vitro pharmacokinetic studies. LC-MS analysis was performed on a platform comprising a Thermo Scientific Dionex Ultimate 3000 and a Bruker amaZon SL equipped with an electrospray ionization source controlled by Bruker Hystar 3.2. Chromatographic separation was performed by injecting 5 mL of the sample onto an Agilent Eclipse Plus C18 column (2.1 mm × 50 mm, 3µm particle size) maintained at 20 °C. The flow rate was maintained at 400 mL/min. The initial flow conditions were 80% solvent A (95:5:0.1 water:methanol:acetic acid with 10 mM ammonium acetate) and 20% solvent B (methanol containing 0.1% acetic acid). Solvent B was maintained at 20% for the first minute of the run and was raised to 80% over 0.50 min. Solvent B was raised to 100% by 5 min and was lowered back to initial conditions (20%) by 8.750 min with a total run time of 12.0 min. The retention times and m/z values are summarized in Supplementary Table 1 . The area of the base peak chromatogram for each compound was measured at each time-point and compared against the zero-minute time point to calculate the percentage of compound remaining at each time point. For samples where the percentage of compound remaining was greater than 100% at the second time point, the second time point was used to calculate the percentage of compound remaining. The data were plotted in Prism 7 and the data fit with a one-phase linear decay model with y 0 value set to 100 to calculate the half-life. For compounds with half-lives greater than 2 h, the percentage of compound remaining after 120 min is reported.
Statistical analysis.
The data reported in this study represent the mean and s.d. of at least three independent experiments measured in triplicate, unless otherwise stated in the figure legend. For statistical analyses, ANOVA and twotailed Student's t-tests were conducted to assess whether a significant difference exists between two groups of samples. A P value of less than 0.05 was considered statistically significant. All statistical tests were carried out using Prism 7 software (GraphPad).
Data availability.
The data that support the findings of this study are available from the corresponding authors upon request. Corresponding author(s): Brent Stockwell, Keith Woerpel
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No sample size calculations were performed. Experiments were performed with three replicates for each treatment group in order to observe variance. Experiments were performed three times to ensure reproducibility and accuracy.
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Describe any data exclusions. No exclusions
Replication
Describe whether the experimental findings were reliably reproduced.
All attempts at replication were successful
Randomization
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Prior to beginning an experiment, cells were seeded/allocated into wells in the same manner for each sample group. When an experiment was commenced, groups of cells were allocated into treatment groups without pattern or bias. This ensured that each treatment group in an experiment were identical (within the inherent variation caused by cell seeding).
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